Lothar Färber

1.4k total citations
16 papers, 1.1k citations indexed

About

Lothar Färber is a scholar working on Pediatrics, Perinatology and Child Health, Immunology and Oncology. According to data from OpenAlex, Lothar Färber has authored 16 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Pediatrics, Perinatology and Child Health, 6 papers in Immunology and 4 papers in Oncology. Recurrent topics in Lothar Färber's work include Pharmacological Effects and Toxicity Studies (5 papers), Drug Transport and Resistance Mechanisms (4 papers) and Psoriasis: Treatment and Pathogenesis (4 papers). Lothar Färber is often cited by papers focused on Pharmacological Effects and Toxicity Studies (5 papers), Drug Transport and Resistance Mechanisms (4 papers) and Psoriasis: Treatment and Pathogenesis (4 papers). Lothar Färber collaborates with scholars based in Germany, United States and Switzerland. Lothar Färber's co-authors include Björn Bauer, Gert Fricker, Harald Gschaidmeier, David S. Miller, Günther Bernhardt, Armin Buschauer, Thilo Spruß, Gottfried Weidinger, G. Mahrle and Gerd Klaus Steigleder and has published in prestigious journals such as Journal of Clinical Investigation, Blood and The American Journal of Medicine.

In The Last Decade

Lothar Färber

16 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Lothar Färber Germany	11	377	251	194	141	138	16	1.1k
Candace Graff United States	10	343 0.9×	201 0.8×	92 0.5×	189 1.3×	78 0.6×	15	983
Gérard F. Murphy Canada	18	252 0.7×	209 0.8×	146 0.8×	227 1.6×	69 0.5×	38	1.1k
Claudio Favre Italy	27	409 1.1×	490 2.0×	303 1.6×	274 1.9×	176 1.3×	94	2.0k
Pamela D. Garzone United States	14	390 1.0×	300 1.2×	445 2.3×	28 0.2×	119 0.9×	33	1.3k
Vanesa Stojanovska Australia	20	462 1.2×	397 1.6×	77 0.4×	142 1.0×	45 0.3×	37	1.3k
Paola Altieri Italy	28	365 1.0×	594 2.4×	212 1.1×	91 0.6×	24 0.2×	77	2.3k
Carlo Avolio Italy	22	306 0.8×	398 1.6×	298 1.5×	40 0.3×	106 0.8×	75	1.8k
Shinobu Mori Japan	13	335 0.9×	190 0.8×	42 0.2×	169 1.2×	24 0.2×	31	787
Silvia Nistri Italy	28	112 0.3×	596 2.4×	140 0.7×	34 0.2×	22 0.2×	69	2.2k

Countries citing papers authored by Lothar Färber

Since Specialization

Citations

This map shows the geographic impact of Lothar Färber's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lothar Färber with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lothar Färber more than expected).

Fields of papers citing papers by Lothar Färber

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lothar Färber. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lothar Färber. The network helps show where Lothar Färber may publish in the future.

Co-authorship network of co-authors of Lothar Färber

This figure shows the co-authorship network connecting the top 25 collaborators of Lothar Färber. A scholar is included among the top collaborators of Lothar Färber based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lothar Färber. Lothar Färber is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

1.

Färber, Lothar, et al.. (2005). Three Generations of Cyclosporine A Formulations: An In Vitro Comparison. Drug Development and Industrial Pharmacy. 31(4-5). 357–366. 9 indexed citations

2.

Vega, Laureano de la, Eduardo Muñóz, Marco A. Calzado, et al.. (2005). The 5-HT3 receptor antagonist tropisetron inhibits T cell activation by targeting the calcineurin pathway. Biochemical Pharmacology. 70(3). 369–380. 73 indexed citations

3.

Bauer, Björn, David S. Miller, Thilo Spruß, et al.. (2002). Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. Journal of Clinical Investigation. 110(9). 1309–1318. 25 indexed citations

4.

Bauer, Björn, David S. Miller, Thilo Spruß, et al.. (2002). Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. Journal of Clinical Investigation. 110(9). 1309–1318. 283 indexed citations

5.

Schopf, R. E., et al.. (2002). A Highly Decreased Binding of Cyclic Adenosine Monophosphate to Protein Kinase A in Erythrocyte Membranes is Specific for Active Psoriasis. Journal of Investigative Dermatology. 119(1). 160–165. 3 indexed citations

6.

Bauer, Björn, David S. Miller, Thilo Spruß, et al.. (2002). Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. Journal of Clinical Investigation. 110(9). 1309–1318. 303 indexed citations

7.

Färber, Lothar, et al.. (2000). Treatment of Fibromyalgia with Intravenous Application of Tropisetron. Journal of Musculoskeletal Pain. 8(4). 31–40. 2 indexed citations

8.

Bondy, Brigitta, Michael Spaeth, Martin Offenbäecher, et al.. (1999). The T102C Polymorphism of the 5-HT2A-Receptor Gene in Fibromyalgia. Neurobiology of Disease. 6(5). 433–439. 137 indexed citations

9.

Otto, Florian, Peter Stütz, Lothar Färber, et al.. (1997). Downregulation of the Proinflammatory Cytokine Response to Endotoxin by Pretreatment With the Nontoxic Lipid A Analog SDZ MRL 953 in Cancer Patients. Blood. 90(4). 1673–1683. 28 indexed citations

10.

Otto, Florian, Peter Stütz, Lothar Färber, et al.. (1997). Downregulation of the Proinflammatory Cytokine Response to Endotoxin by Pretreatment With the Nontoxic Lipid A Analog SDZ MRL 953 in Cancer Patients. Blood. 90(4). 1673–1683. 28 indexed citations

11.

Winkler, Michael, Karl J. Oldhafer, Wolf O. Bechstein, et al.. (1996). A NEW ORAL FORMULATION OF CYCLOSPORINE FOR EARLY ORAL IMMUNOSUPPRESSIVE THERAPY IN LIVER TRANSPLANT RECIPIENTS. Transplantation. 62(8). 1063–1068. 15 indexed citations

12.

Mahrle, G., et al.. (1995). Low-dose short-term cyclosporine versus etretinate in psoriasis: Improvement of skin, nail, and joint involvement. Journal of the American Academy of Dermatology. 32(1). 78–88. 110 indexed citations

13.

Färber, Lothar, et al.. (1995). Long-term maintenance therapy with cyclosporine and posttreatment survey in severe psoriasis: Results of a multicenter study. Journal of the American Academy of Dermatology. 33(3). 470–475. 52 indexed citations

14.

Greten, Heiner, Frank Ulrich Beil, Jürgen E. Schneider, et al.. (1994). Treatment of primary hypercholesterolemia: Fluvastatin versus bezafibrate. The American Journal of Medicine. 96(6). S55–S63. 21 indexed citations

15.

Peter, Ralf Uwe, et al.. (1994). Low‐dose cyclosporin A in palmoplantar psoriasis: evaluation of efficacy and safety. Journal of the European Academy of Dermatology and Venereology. 3(4). 518–524. 3 indexed citations

16.

Winkler, Michael, B. Ringe, Lothar Färber, et al.. (1994). Enhanced bioavailability of cyclosporine using a new oral formulation (Sandimmun optoral) in a liver-grafted patient with severe cholestasis. Transplant International. 7(2). 147–148. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact